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Introduction: Fulminant hepatic failure is a serious disease with significant mortality and morbidity. Identifying the
exact cause of hepatic failure and predicting prognosis is of paramount importance in managing such patients.
Drug-induced liver injury is a common but challenging entity to treat. The use of newer drugs and medications
with previously unknown hepatotoxicity add to the challenges faced by treating physicians. Quetiapine is an
antipsychotic that has rarely been linked to acute liver injury. In the present work we describe a case of fulminant
hepatic failure secondary to use of quetiapine.
Case presentation: A 59-year-old Caucasian woman with known Parkinson’s disease was being treated with
quetiapine for hallucinations. She was referred to our hospital with yellow discoloration of the sclera and later on
developed clinical features suggestive of hepatic encephalopathy. A diagnosis of fulminant hepatic failure was
made following her admission to the intensive care unit. Her condition improved after discontinuing the drug and
providing the standard supportive treatment.
Conclusions: Our findings in the present report emphasize the importance of keeping an open mind in cases of
fulminant hepatic failure. As drug-induced hepatotoxicity is the most common cause of fulminant hepatic failure in
many parts of the world, consideration should be given to the medication(s) patients receive as the potential cause
and a review of this list should be part of the clinical care given.
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Fulminant hepatic failure (FHF) is defined by the rapid
development of severe acute liver injury accompanied by
synthetic dysfunction and the development of encephalop-
athy in an individual with either a previously normal liver
or well compensated liver disease [1,2]. Proposed defini-
tions of the time course for fulminant hepatic failure
include the development of encephalopathy within eight
weeks of the onset of symptoms in a patient with a previ-
ously healthy liver [1] or the appearance of encephalopathy
within two weeks of developing jaundice, in a patient with
or without previous underlying liver dysfunction [2].
Although, FHF can result from a wide variety of causes,
drug-induced hepatoxicity is common, causing high mor-
tality with an estimated 3.5 deaths per million people in the
US alone [3]. The reported short-term survival is 49%* Correspondence: talameel@gmail.com
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reproduction in any medium, provided the oralthough the outcome of FHF has significantly improved
with the introduction of liver transplantation [4].
Quetiapine (SeroquelW; AstraZeneca) is an atypical
antipsychotic agent used to control positive and negative
symptoms in patients with psychosis [5]. It has a low
side effect profile and is generally well tolerated in doses
from 150 to 750mg/day [6]. The common known side
effects of quetiapine include a mild asymptomatic dis-
turbance of liver enzymes, leukopenia, pancytopenia and
thrombotic thrombocytopenic purpura [7,8]. Rarely, neuro-
leptic malignant syndrome, hyperprolactinemia, myoclonus
and cardiac arrhythmias have also been reported as adverse
effects [9-12]. We describe the case of a patient with FHF
caused by quetiapine, a rarely reported adverse effect of this
drug associated with significant mortality if not identified
and treated early [13-15].
Case presentation
A 59-year-old Caucasian woman with a prior history
of Parkinson’s disease was on carbidopa-levodoparal Ltd. This is an Open Access article distributed under the terms of the Creative
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pramipexole for six months before she developed
hallucinations that were attributed to pramipexole
therapy. Subsequently, pramipexole was discontinued
and our patient was given quetiapine to treat her
hallucinations. She had received six weeks of quetiapine
therapy before presenting to our hospital with the main
complaint of feeling unwell for three weeks. Her symptoms
were accompanied with nausea, vomiting, decrease appetite
and abdominal pain for a few days duration. She had also
noticed a yellowish discoloration of her sclera but no
change in the color of urine or stool. There was no
accompanying history of fever, chills or rigors. No risk
factors or history suggestive of familial liver disease was
provided. She was a non-smoker and denied drinking
alcohol.
The results of a general physical examination revealed
a stable hemodynamic status with bilateral icterus but
no pallor, cyanosis or lymphadenopathy. An abdominal
examination demonstrated distention with tenderness in
the right upper quadrant but no clinically detectable
ascites or hepatosplenomegaly. No other stigmata of
chronic liver disease were seen. Cardiovascular and respira-
tory system examinations were unremarkable. No abnor-
mality was detected on the neurological examination.
Admission blood test results showed a normal hemo-
gram and normal renal function tests including electrolytes
but deranged liver function tests (alanine aminotransferase:
71IU/L; aspartate aminotransferase: 740IU/L; lactate
dehydrogenase: 737IU/L; γ-glutamyl transferase: 509IU/L;
alkaline phosphatase: 196IU/L; total bilirubin: 244μmol/L
and an international normalized ratio (INR) of 2.7). Her
blood ethanol level was in the normal range. Viral serology
test results for hepatitis A, B and C were negative. A vascu-
litic screen was performed, which revealed an anti-nuclear
antibody titer of 1:1600 and positive anti-double-stranded
deoxyribonucleic acid (dsDNA) results, but negative results
for anti-liver kidney microsomal antibody. Tests for
anti-neutrophil cytoplasmic antibodies showed negative
results for anti-myeloperoxidase but were equivocal
for anti-proteinase 3. Normal α-1 anti-trypsin levels
(1.89μmol/L) and normal levels for other immunoglobulins
were found (IgG: 34g/L, IgA: 2.44g/L and IgM: 1.5g/L).
The results of screening tests for Wilson’s disease and
hemochromatosis were also negative.
An ultrasound scan of the abdomen showed a
distended gall bladder with absence of stones and no
free fluid in the abdomen. The liver and spleen sizes
were reported as within normal ranges. Computerized
tomography of the abdomen confirmed the absence of
intra-hepatic biliary dilatation.
In view of the above-mentioned findings and her history,
our patient was admitted with a probable diagnosis of
quetiapine-induced hepatitis. Quetiapine was discontinuedbut other medications, that is, carbidopa-levodopa and
oxazepam, were not stopped. The initial treatment was
mainly supportive. However, within 48 hours of admission,
our patient demonstrated signs of encephalopathy in the
form of confusion, astrexis and impaired level of con-
sciousness with the development of significant ascitis. She
was subsequently transferred to the intensive care unit and
the local liver transplant team was consulted for probable
transplant. After ruling out spontaneous bacterial periton-
itis, our patient was treated with lactulose, spironolactone
and furosemide. She was also given methyprednisolone
20mg intravenously. A follow-up abdominal ultrasound
scan revealed splenomegaly, coarse liver parenchyma and
ascitis but no focal lesions or cholelithiasis. The hepatic
and portal circulations were patent on Doppler examin-
ation. A trans-jugular liver biopsy confirmed extensive
confluent and bridging necrosis predominantly in zone 3.
The portal area contained mild to focally moderate mixed
inflammatory cellular infiltrate consisting of lymphocytes,
macrophages, eosinophils and a few polymorphonuclear
cells along the boundaries of the necrotic areas. The
parenchyma showed variable degrees of hepatocellular
degeneration and mild mixed inflammatory cellular
infiltrate consisting mainly of lymphocyes and macro-
phages with few plasma cells and prominent Kupffer
cells. The overall histopathological picture was reported
to be suggestive of an acute hepatitis with confluent
and bridging necrosis, indicative of drug-induced liver
injury.
Our patient’s clinical symptoms improved gradually
accompanied by improvement in biochemical parameters
over the course of her stay in the intensive care unit. The
encephalopathy resolved completely with improvement in
icterus, nutritional status and oral intake. Later on, she was
transferred out of the intensive care unit to the general
ward and put on a tapering dose of oral prednisolone
starting at 40mg/day.
She was discharged home in a stable condition
approximately six weeks after the initial admission on
20mg prednisolone per day with a suggested tapering of
5mg every week. She was advised against taking quetiapine
in the future. Follow-up blood test results eight weeks after
discharge revealed mildly elevated liver enzymes (less than
twice the upper limit of normal) with normal synthetic and
excretory hepatic functions.
Discussion
Quetiapine is a dibenzothiazepine, an atypical antipsychotic
agent that is known to have a positive effect on positive
and negative symptoms of psychosis [5]. Although its
mechanism of action is poorly understood, it is thought to
exert its effect through a combination of dopamine (D2)
and 5-hydroxytryptamine-2 (5HT2) receptor antagonism.
Quetaipine demonstrates a heterogenic antagonist activity
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compared to D2. It also has affinities for a range of other
neurotransmitter receptors such as serotonin 5HT1a, D1,
histamine-1 and adrenergic α-1 and α-2. It has, however,
no appreciable affinities for cholinergic muscarinic and
benzodiazepine receptors [16]. It is metabolized via the
hepatic mixed function oxidase system using the cyto-
chrome P450 3A4 isoenzyme [5]. Quetiapine [17] was
considered to be a non-hepatotoxic drug except for a mild
and transient asymptomatic elevation of liver enzymes
prior to the first published report of quetiapine-induced
FHF by El Hajj et al. in 2004 [13].
The most likely etiology in our patient’s case was
quetiapine-induced liver injury. Other possible etiologies
such as viral hepatitis A, B and C, metabolic disorders
including Wilson’s disease and vascular diseases such as
Budd-Chiari syndrome were ruled out. The other
diagnosis considered with such a presentation is ‘FHF of
unknown etiology’, which accounts for 17% of FHF cases
[18]. However, the temporal association between the
commencement of the medication and the onset of her
symptoms strongly indicates the possibility of quetiapine
as the culprit agent. The other differential diagnosis that
was considered was of autoimmune hepatitis due to the
elevated anti-nuclear antibody level found in our patient.
However, anti-nuclear antibody elevation is a non-
specific finding and can also be seen in drug-induced
hepatic injury. Moreover, in absence of other serological
markers and absence of findings on liver biopsy, an auto-
immune etiology is very unlikely. Of note, acute liver injury
secondary to autoimmune process or drug toxicity shows
response to steroid therapy in both cases. Also, extensive
zone 3 predominant necrosis (as seen in our patient) on
liver biopsy is seen in drug-induced liver injury [19]. Indeed,
on the Roussel Ucalf Causality Assessment Method/
Council for International Organizations of Medical Sciences
scoring system our patient had a score of 7, indicating
probable causation of FHF by quetiapine [20,21].
In cases of FHF, the decision for liver transplantation
is based on clinical judgment and utilization of prognostic
criteria such as the King’s College criteria. For known
acetaminophen-induced FHF, the criteria include: disease
etiology (cryptogenic/toxin), age (<10 years, >40 years),
duration of jaundice (more than one week before the
development of encephalopathy), serum bilirubin concen-
tration of 18mg/dl and INR >3.5, our patient fulfilled only
three of these five criteria [22]. Complete resolution
except for minimal elevation of liver enzymes was the final
outcome in our patient as opposed to mortality in two
other cases of quetiapine-induced liver injury reported in
the literature [13]. One other case reported by Shpaner et
al. showed improvement after quetiapine cessation, which
may have been due to subfulminant rather than fulminant
hepatic failure [15].Conclusions
Our patient’s case emphasizes the importance of keeping
an open mind in cases of fulminant hepatic failure. As
drug-induced hepatotoxicity is the most common cause
of fulminant hepatic failure in many parts of the world,
consideration should be given to the medication(s)
patients receive as being the potential cause, and a
review of the list should be part of the clinical care
administered.
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